SIRPant Immunotherapeutics Strengthens Board of Directors with Appointment of Roger Sawhney, M.D.
HUMMELSTOWN, Pa., Jan. 22, 2024 (GLOBE NEWSWIRE) -- SIRPant Immunotherapeutics, Inc., a clinical-stage immuno-oncology company focusing on developing next-generation macrophage-based immunotherapies for the treatment of hematological malignancies and solid tumors, today announced the appointment of Roger Sawhney, M.D.
- HUMMELSTOWN, Pa., Jan. 22, 2024 (GLOBE NEWSWIRE) -- SIRPant Immunotherapeutics, Inc., a clinical-stage immuno-oncology company focusing on developing next-generation macrophage-based immunotherapies for the treatment of hematological malignancies and solid tumors, today announced the appointment of Roger Sawhney, M.D.
- to its Board of Directors.
- Dr. Sawhney brings nearly 30 years of financial and strategic expertise spanning the biopharma industry.
- His expertise in cell therapy will be particularly valuable to SIRPant as we advance SIRPant-M™, our lead product candidate, into clinical development,” said Robert Towarnicki, President & CEO of SIRPant.